Third-Party Gametes/Gestational Carriers and ART
Donor sperm is widely available through commercial sperm banks with cryopreserved sperm. The development of ICSI has dramatically reduced the demand for donor sperm.
Pregnancy rates with in vitro fertilization declines substantially after the age of 37 due to poor oocyte quality. Oocyte donation allows women over the age of 40, premature ovarian failure and prior failed IVF attempts an option. Texas statue declares the recipients of donated oocytes the legal parents of any conceived offspring.
A gestational carrier may be a woman who serves as an oocyte donor and carrier, usually through artificial insemination, with the resulting offspring adopted by the recipient couple. In 1996, 111 programs reported performing host uterus cycles. A total of 688 cycles were initiated with 86.8 percent transfers per cycle. Delivered pregnancies rates were 31.3 percent per transfer.
R E F E R E N C E S :
1. Donini P, Puzzuoli D, MontezemoloR. Purification of gonadotropin from human menopausal urine. Acta Endocrinol 1964;45:321.
2. Chang MC. Fertilizing capacity of spermatozoa deposited into the fallopian tubes. Nature 1951:168.
3. Gordon JW, Talansky BE. Assisted fertilization by zona drilling a model for correction of oligospermia. J Exp Zool 1986;239:347.
4. Jones HW, Jones GS, Andrews MC, et al. The program of in vitro fertilization at Norfolk. Fertil Steril 1982;38:14.
5. Keay SD, Liversedge HH, Mathur RS, et al. Assisted conception following poor ovarian response to gonadotropin stimulation. Br J Obstet Gynaecol 1997;104:521.
6. Malter HE, Cohen J. Partial zona dissection of the human oocyte: a nontraumatic method using micromanipulation to assist zona pellucida penetration. Fertil Steril 1989;51:139.
7. Palermo G, Joris H, Devroey P, et al. Pregnancies after intracytoplasmic injection of single spermatozoan into an oocyte. Lancet 1992;340:17.
8. Olivenes F, Alvarez S, Bouchard P, et al. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Human Reprod 1998;13:2411.
9. Perone N. In vitro fertilization and embryo transfer: a historical perspective. J Reprod Med 1994;39:695.
10. Rock J, Menkin MF. In vitro fertilization and cleavage of human ovarian eggs. Science 1944;100:105.
11. Scholtes MCW, Zeilmaker GH. A prospective randomized study of embryo transfer results after 3 or 5 days of embryo culture in in vitro fertilization. Fertil Steril 1996;65:1245.
12. Steinkampf MP, Kretzer PA, McElroy E, et al. A simplified approach to in vitro fertilization. J Reprod Med 1992;37:199.
13. Steptoe PC, Edwards RG. Birth after the implantation of a human embryo. Lancet 1978;2:336.
14. Steptoe PC, Edwards RG. Report on human in vitro fertilization with subsequent tubal pregnancy. Lancet 1976;1:880.
15. The American Fertility Society, Society for Assisted Reproductive Technology. Assisted reproductive technology in the United States: 1996 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril 1999;71:798.
16. The Ganirelix Dose-Finding Study Group. A double-blind randomized, dose-finding study to assess the efficacy of the gonadotropin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian hyperstimulation with recombinant follicle stimulating hormone (Puregon). Human Reprod 1998;13:3023.Physician Resources